Seattle-based biotech company NanoString Technologies Inc. has expressed grave concerns to a Delaware court over the potential consequences of rival 10x Genomics’ bid to double a $31 million award. The increased award, a result of a jury’s November finding of willful infringement by NanoString, could force the company into bankruptcy, with far-reaching impact on both patients and the general public, NanoString argued.
The dispute between NanoString and 10x Genomics revolves around patented technologies related to genetic solutions. This case has garnered significant attention from legal and business observers due to its potential to set precedents for future intellectual property conflicts in the fast-evolving biotech sphere.
As this tense legal battle continues to unfolds, many in the legal community anxiously await the court’s decision and the impact it could potentially have on the future health and viability of innovator companies like NanoString.
The stakes, as NanoString put it, could not be higher. As they face the threat of insolvency, the Seattle biotech company is not just fighting for its survival, but also for the necessary continuation of its work, which could be of significant importance to patients and the wider public.